伊布替尼联合利妥昔单抗一线治疗慢性淋巴细胞白血病评估(FLAIR试验):III期随机对照试验研究方案
FLAIR是一项III期多中心随机对照开放平行组试验,计划入组754例初治慢性淋巴细胞白血病患者,1:1随机接受FCR标准方案或伊布替尼联合利妥昔单抗(IR),主要终点为无进展生存期(PFS)。该试验旨在评估IR在PFS方面是否优于FCR,以及毒性率是否更有利。
要点
- FLAIR为III期随机对照试验,比较IR与FCR一线治疗初治CLL的PFS。
- 计划入组754例,1:1随机,主要终点为IWCLL标准的PFS。
- IR组利妥昔单抗6个28天周期,伊布替尼每日口服最长6年。
核心结论
- 该试验旨在通过评估IR在PFS方面是否优于FCR以及毒性率是否更有利,为CLL患者未来一线治疗提供证据。
研究设计与样本
- FLAIR为III期、多中心、随机、对照、开放、平行组试验,纳入既往未治疗的CLL患者。
- 共754名参与者将按1:1随机接受FCR标准治疗或IR治疗。
主要发现
- 分配至FCR的参与者最多接受六个28天治疗周期。
- 分配至IR的参与者接受六个28天周期的利妥昔单抗,并每日服用伊布替尼6年,直至达到微小残留病(MRD)阴性并持续与达到MRD阴性所需相同的时间,或直至疾病进展。
- 主要终点为根据国际慢性淋巴细胞白血病工作组(IWCLL)标准的PFS。
- 次要终点包括:总生存期;MRD检测不到的患者比例;按IWCLL标准的治疗反应;安全性与毒性;健康相关生活质量(QoL);以及成本效益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line therapy. However, the majority of patients relapse and require further therapy, and so new, effective, targeted therapies that improve remission rates, reduce relapses, and have fewer side effects, are required. The FLAIR trial will assess whether ibrutinib plus rituximab (IR) is superior to FCR in terms of progression-free survival (PFS). METHODS/DESIGN: FLAIR is a phase III, multicentre, randomised, controlled, open, parallel-group trial in patients with previously untreated CLL. A total of 754 participants will be randomised on a 1:1 basis to receive standard therapy with FCR or IR. Participants randomised to FCR will receive a maximum of six 28-day treatment cycles. Participants randomised to IR will receive six 28-day cycles of rituximab, and ibrutinib taken daily for 6 years until minimal residual disease (MRD) negativity has been recorded for the same amount of time as it took to become MRD negative, or until disease progression. The primary endpoint is PFS according to the International Workshop on CLL (IWCLL) criteria. Secondary endpoints include: overall survival; proportion of participants with undetectable MRD; response to therapy by IWCLL criteria; safety and toxicity; health-related quality of life (QoL); and cost-effectiveness. DISCUSSION: The trial aims to provide evidence for the future first-line treatment of CLL patients by assessing whether IR is superior to FCR in terms of PFS, and whether toxicity rates are favourable. TRIAL REGISTRATION: ISRCTN01844152 . Registered on 8 August 2014, EudraCT number 2013-001944-76 . Registered on 26 April 2013.
引用
- Collett L, Howard DR, Munir T, et al. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials. 2017. PMID: 28830517. doi:10.1186/s13063-017-2138-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。